Phreesia, a healthcare SaaS company, is facing a class action lawsuit from investors who bought its stock between May 2025 and March 2026. The lawsuit alleges Phreesia misled investors by not disclosing weakening pharmaceutical marketing commitments and reduced visibility into future spending within its Network Solutions segment. In March 2026, Phreesia lowered its fiscal 2027 revenue forecast from $545-$559 million to $510-$520 million, citing lower client spending and increased variability in revenue forecasting. Following this, the stock price dropped about 27%. Investors may participate in the class action, with a lead plaintiff deadline of July 13, 2026.
Canada's proposed Bill C-22 faces strong opposition from major tech firms like Meta, Apple, and Signal, as well as VPN providers, due to concerns it could force companies to weaken encryption and compromise digital privacy. Industry leaders warn this...
Bill C-22 in Canada faces strong opposition from tech leaders and experts who warn it threatens the digital economy by undermining data privacy and encryption. Quebec's tech sector, especially in AI and cloud infrastructure, could lose investments, t...
Sandisk's stock has surged 476% in 2026, driven by strong demand for storage linked to the AI boom and impressive revenue growth, including a 97% quarter-over-quarter increase to $5.9 billion. The company boasts high profit margins and optimistic Wal...
The iShares MSCI Europe Financials ETF (EUFN) has modestly outperformed its US counterparts in 2026, even as the financial sector overall lags behind the S&P 500. This performance occurs amid weak but positive GDP growth in Europe, with central banks...
Frank Holmes, CEO of U.S. Global Investors, highlighted that despite recent volatility in airline stocks due to geopolitical tensions and rising fuel costs, global travel demand remains robust. He noted strong international travel between North Ameri...
